Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Document Type
Journal Article
Publication Date
2-1-2016
Journal
Arteriosclerosis, Thrombosis and Vascular Biology
Volume
36
Issue
2
Inclusive Pages
418-424
DOI
10.1161/ATVBAHA.115.306905
Keywords
Activated Protein C Resistance--complications; Coronary Disease--chemically induced; Estrogen Replacement Therapy--adverse effects; Estrogens--adverse effects; Lipoproteins--adverse effects; Progestins--adverse effects
APA Citation
Johnson, K., Aragaki, A., Jackson, R., Reiner, A., Martin, L. W., & +8 additional authors (2016). Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.. Arteriosclerosis, Thrombosis and Vascular Biology, 36 (2). http://dx.doi.org/10.1161/ATVBAHA.115.306905
Peer Reviewed
1